<DOC>
	<DOCNO>NCT02426632</DOCNO>
	<brief_summary>The primary objective evaluate double-blinded ( neither physician participant know treatment participant receives ) , fashion taste different JNJ-53718678 oral liquid formulation compare reference formulation ( JNJ-53718678 , 10 milligram/milliliter oral solution without sweetener/flavor ) .</brief_summary>
	<brief_title>Study Evaluate Taste Profile Different JNJ-53718678 Oral Liquid Formulations Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , double-blind , randomize ( participant taste group drug [ formulation ] random order ) , single-center trial healthy adult participant . The study include 2 Sessions 1 day , 1 ) Session 1 , participant receive 6 JNJ-53718678 oral solution ( 1 reference 5 different formulation ) sequentially randomize order , Scoring taste do via questionnaire design purpose ; 2 ) Session 2 , within approximately timeframe 7 14 day completion Session 1 , participant taste 2 best score taste come Session 1 . The study consist screen phase approximately 2 week , treatment phase approximately 2 week post-treatment follow-up phase 10 day completion last Session . The total study duration participant approximately 6 week .</detailed_description>
	<criteria>Female participant childbearing potential urine pregnancy test screen negative Participants must nonsmoker and/or use chew tobacco least one month prior screen Participants must willing/able adhere prohibition restriction specify protocol study procedures Participants must able taste smell normally , opinion , time throughout study duration . Participants impaired sense taste and/or smell due condition like common cold sinusitis eligible take part continue study Participants must agree use adequate method contraception Participant mouth pathology include , limited , pain , ulcer , edema , mucosal erosion , and/or ( dental ) abscess , receive treatment oral pathology oral treatment disease Participant history illness , opinion Investigator , might confound result study pose additional risk administer study drug participant could prevent , limit confound protocol specify assessment . This may include limited renal dysfunction , significant cardiac , vascular , pulmonary , gastrointestinal ( significant diarrhea , gastric stasis , constipation Investigator 's opinion could influence drug absorption bioavailability ) , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Participants history clinically significant allergy , hypersensitivity , intolerance drug , limit , sulfonamide penicillin , drug allergy witness previous study experimental drug , JNJ53718678 excipients Participants history evidence use alcohol , barbiturate , amphetamine , recreational narcotic drug use within past 3 month , Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participants receive investigational drug ( include investigational vaccine ) use invasive investigational device within 3 month plan first dose study drug currently enrol investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-53718678</keyword>
</DOC>